Overview

Safety and Efficacy of RHH646 for Knee Osteoarthritis

Status:
Not yet recruiting
Trial end date:
2026-01-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis. The treatment duration will be up to 52 weeks. The total study duration for an individual participant will be up to 62 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals